Evaluating the benefits of continued ovarian function suppression for breast cancer after 5 years

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the clinical efficacy and safety of continuing ovarian function suppression (OFS) in premenopausal women diagnosed with early hormone receptor positive, HER2 negative breast cancer after they have completed 5 years of OFS treatment. The study will involve two cohorts: one that continues OFS and another that discontinues it, with data collected from hospital medical records over a three-year period. By comparing outcomes between these groups, the study seeks to provide insights into the long-term benefits of sustained OFS therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with early primary breast cancer
* Female aged 18-60 years (including 18 year and 60 year)
* Hormone receptor (HR) positive HER2 negative
* Receive 5 years of OFS treatment
* ECOG score 0-1
* Voluntarily join this study and sign the informed consent form;
* The researcher believes that it can benefit.

Exclusion Criteria:

* The patient is receiving treatment that affects OFS at the same time The patient has received OFS treatment for less than 5 years
* Central nervous system metastases with known obvious symptoms, such as headache, cerebral edema, blurred vision
* Invasive metastases with known obvious symptoms
* Invasive metastases with known obvious symptoms
* Doctors think it is not suitable for inclusion

Where it's running

• Wu Xinhong
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Hongmei Zheng, Doctor — Study Principal Investigator
• Study coordinator: Hongmei Zheng, Doctor
• Email: zhenghongmeicj@163.com
• Phone: 18971624606

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• Negative pressure wound therapy after mastectomy

  This study tests whether a negative pressure dressing after mastectomy reduces fluid build‑up and common wound complications in women with breast cancer.

  Recruiting Dalarna County Council, Sweden · Falun · NCT07607366

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• Adherence to Cell Cycle Inhibitors with Endocrine Therapy in Localized High-Risk ER+ Breast Cancer

  This study checks how well patients with localized ER+ breast cancer stick to a combined endocrine therapy and CDK4/6 inhibitor after surgery.

  Recruiting University Hospital, Grenoble · Grenoble · NCT07443774

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.